Brahmy Dan 4

What Happened

• Brahmy Dan, Chief Executive Officer of Cyabra, Inc. (CYAB), was issued a total of 711,548 shares/awards on March 27, 2026. This consists of 535,402 shares received in connection with the Issuer's business combination, 134,000 restricted stock units (RSUs) granted under the 2026 Omnibus Equity Incentive Plan (fully vested on grant), and 42,146 derivative shares (options/other equity awards) reported as acquired. The 134,000 RSUs show a $0.00 per‑share grant price (i.e., no cash paid). The other items are the result of merger conversions and equity-plan grants.

Key Details

• Transaction date: March 27, 2026. Filing date: March 31, 2026 (timely filed within the required period).
• Breakout: 535,402 shares (merger conversion), 134,000 RSUs @ $0.00 (fully vested on grant), 42,146 derivative awards (converted/granted options/derivatives; fully vested upon grant per filing).
• Footnotes of note:
  • Conversion from pre-merger Cyabra ordinary shares pursuant to the Merger Agreement (business combination with Trailblazer Merger Corporation I).
  • 148,324 pre‑merger Cyabra ordinary shares held by the reporting person converted into 535,402 Issuer shares.
  • Some shares are held in trust by IBI Trust Management for the reporting person.
  • RSUs and options were fully vested upon grant; certain pre‑merger options were cancelled and replaced with Issuer options on the same terms.
• Shares owned after the reported transactions: not disclosed in the filing.

Context

• These are awards/grants and merger conversion transactions (code A) — not open‑market purchases or sales. They do not reflect a cash purchase or sale by the insider.
• The 134,000 RSUs were fully vested on grant, meaning the CEO received vested equity immediately; the derivative awards/options were also reported as fully vested on grant. That does not necessarily mean immediate sale; any transferability or sale could be subject to plan rules, lock‑ups, or tax withholding.
• Because these were merger-related conversions and plan grants rather than purchases/sales, they should be interpreted as corporate‑action and compensation events rather than direct insider sentiment about the stock price.